LAB Stock Overview
Provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Standard BioTools Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.61 |
| 52 Week High | US$3.04 |
| 52 Week Low | US$1.21 |
| Beta | 1.57 |
| 11 Month Change | -14.36% |
| 3 Month Change | -17.44% |
| 1 Year Change | -32.07% |
| 33 Year Change | -64.30% |
| 5 Year Change | -35.60% |
| Change since IPO | -88.52% |
Recent News & Updates
Standard BioTools (NASDAQ:LAB) Has Debt But No Earnings; Should You Worry?
Oct 26
Market Participants Recognise Standard BioTools Inc.'s (NASDAQ:LAB) Revenues Pushing Shares 33% Higher
Sep 14Recent updates
Standard BioTools (NASDAQ:LAB) Has Debt But No Earnings; Should You Worry?
Oct 26Market Participants Recognise Standard BioTools Inc.'s (NASDAQ:LAB) Revenues Pushing Shares 33% Higher
Sep 14Newsflash: Standard BioTools Inc. (NASDAQ:LAB) Analysts Have Been Trimming Their Revenue Forecasts
Aug 05Revenues Tell The Story For Standard BioTools Inc. (NASDAQ:LAB) As Its Stock Soars 42%
Jul 26Is It Time To Consider Buying Standard BioTools Inc. (NASDAQ:LAB)?
Apr 09Estimating The Fair Value Of Standard BioTools Inc. (NASDAQ:LAB)
Mar 06Standard BioTools Inc.'s (NASDAQ:LAB) P/S Still Appears To Be Reasonable
Feb 17Health Check: How Prudently Does Standard BioTools (NASDAQ:LAB) Use Debt?
Jan 12Is Standard BioTools (NASDAQ:LAB) A Risky Investment?
Aug 13Fluidigm Corporation: Investment Opportunity
Jan 26Shareholder Returns
| LAB | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -12.5% | -5.8% | -1.0% |
| 1Y | -32.1% | 1.7% | 30.3% |
Return vs Industry: LAB underperformed the US Life Sciences industry which returned 1.2% over the past year.
Return vs Market: LAB underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| LAB volatility | |
|---|---|
| LAB Average Weekly Movement | 9.4% |
| Life Sciences Industry Average Movement | 8.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: LAB has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: LAB's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 537 | Michael Egholm | www.standardbio.com |
Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.
Standard BioTools Inc. Fundamentals Summary
| LAB fundamental statistics | |
|---|---|
| Market cap | US$562.11m |
| Earnings (TTM) | -US$170.60m |
| Revenue (TTM) | US$155.90m |
3.8x
P/S Ratio-3.5x
P/E RatioIs LAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LAB income statement (TTM) | |
|---|---|
| Revenue | US$155.90m |
| Cost of Revenue | US$80.19m |
| Gross Profit | US$75.71m |
| Other Expenses | US$246.32m |
| Earnings | -US$170.60m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.46 |
| Gross Margin | 48.57% |
| Net Profit Margin | -109.43% |
| Debt/Equity Ratio | 11.3% |
How did LAB perform over the long term?
See historical performance and comparison